P/E of Retrophin, Inc.
The price to earnings ratio is the most widely used method for determining whether shares are accurately valued in relation to one another. But the P/E ratio does not in itself indicate whether the share is a bargain. The P/E ratio depends on the market’s perception of the risk and future growth in earnings. A company with a low P/E ratio indicates that the market perceives it as a higher risk or a lower growth or both as compared to a company with a higher price to earnings ratio. The P/E ratio of a listed company’s stock is the result of the collective perception of the market as to how risky the company is and what its earnings growth prospects are in relation to that of other companies. Investors use the P/E ratio to compare their own perception of the risk and growth of a company against the market’s collective perception of the risk and growth as reflected in the current P/E ratio.
Retrophin, Inc., a biopharmaceutical company, focuses on the development, acquisition, and commercialization of therapies for the treatment of serious or rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, and for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria. The company's product candidates consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis; Fosmetpantotenate, a novel small molecule that is in Phase III clinical trial to treat pantothenate kinase-associated neurodegeneration; Tetracosactide Zinc (RE-034), a synthetic hormone analog that is in preclinical stage; and Liquid Ursodeoxycholic Acid, a liquid formulation of ursodeoxycholic acid, which is in preclinical stage to treat primary biliary cholangitis. Retrophin, Inc. was founded in 2011 and is headquartered in San Diego, California.
|FOF Cohen & Steers Closed-End Opportunity Fund, Inc.||NYSE > Finance > Closed-End Fund - Equity||139.26%|
|ACIU AC Immune SA||NASDAQ > Health Care > Major Pharmaceuticals||139.80%|
|BH Biglari Holdings Inc.||NYSE > Consumer Services > Restaurants||141.24%|
|FNJN Finjan Holdings, Inc.||NASDAQ > Miscellaneous > Multi-Sector Companies||143.04%|
|AST Asterias Biotherapeutics, Inc.||NYSEMKT > Health Care > Biotechnology: Biological Products (No Diagnostic Substances)||143.39%|
|GLBL TerraForm Global, Inc.||NASDAQ > Public Utilities > Electric Utilities: Central||143.65%|
|RTRX Retrophin, Inc.||NASDAQ > Health Care > Major Pharmaceuticals||143.96%|
|EMITF Elbit Imaging Ltd.||NASDAQ > Consumer Services > Building operators||8,567.32%|
|ARWR Arrowhead Pharmaceuticals, Inc.||NASDAQ > Health Care > Major Pharmaceuticals||9,838.97%|
|KALV KalVista Pharmaceuticals, Inc.||NASDAQ > Health Care > Major Pharmaceuticals||10,692.86%|
|ACAD ACADIA Pharmaceuticals Inc.||NASDAQ > Health Care > Major Pharmaceuticals||14,131.15%|
|CYAD Celyad SA||NASDAQ > Health Care > Major Pharmaceuticals||149,734.18%|
|VLRX Valeritas Holdings, Inc.||NASDAQ > Health Care > Medical/Dental Instruments||246,776.16%|